Healthcare
Live Price
Offline$10.88
-1.09% today
1Y Change
+16.16%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Phathom Pharmaceuticals, Inc. (PHAT) is a Healthcare stock with a market cap of $950.00M and listed on NASDAQ. The stock last traded around $10.88 and up 16.2% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +216.9%, EPS growth of +42.7%, a dividend yield of 0.0%. What stands out right now is revenue +216.9%, EPS +42.7%, free cash flow +37.5% with operating margin -47.1% and ROIC -53.4%. Valuation sits in the middle of the pack at price/sales 4.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PHAT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHAT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHAT Max Drawdown
-48.89%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHAT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$143.9M
+27.2% YoY
Free Cash Flow
-$148.8M
-0.8% YoY
Revenue Growth
+216.9%
EPS Growth
+42.7%
Gross Margin
84.9%
Net Margin
-76.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 175M | 55M | 682K | 0 | 0 |
| Gross Profit | 153M | 47M | 515K | -620K | -521K |
| Operating Income | -160M | -277M | -167M | -172M | -135M |
| EBITDA | -152M | -262M | -159M | -170M | -137M |
| Net Income | -221M | -334M | -202M | -198M | -144M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 130M | 297M | 381M | 155M | 183M |
| Total Assets | 259M | 378M | 414M | 165M | 189M |
| Total Liabilities | 697M | 632M | 487M | 240M | 117M |
| Shareholder Equity | -438M | -254M | -73M | -75M | 72M |
| Total Debt | 3M | 555M | 139M | 97M | 91M |
| Net Debt | -127M | 258M | -242M | -58M | -92M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
148M
-1.3% YoY
Capital Expenditures
328K
+68.5% YoY
Free Cash Flow
149M
-0.8% YoY
Key ratios
Gross Margin
84.9%
Operating Margin
-47.1%
Net Margin
-76.8%
ROE
39.2%
Debt / Equity
-0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.